Concepedia

Michael J. Munchhof

MJ

Statistics

Publications

35

Citations

4K

H-Index

24

Active since

1992

Affiliations

Pfizer (United States)(Current)

Epizyme (United States)

Moores Cancer Center

Michael J. Munchhof is an author at Pfizer (United States) specializing in medicinal chemistry, pharmacology, and drug discovery.

Publications per year

1992–2021

35

Publications

35

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

Chen Zhao, Alan Chen, Catriona Jamieson et al. · Nature · 2009 · 861 citations · Full text

, , +16

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

Paul S. Changelian, Mark E. Flanagan, Douglas J. Ball et al. · Science · 2003 · 670 citations · Full text

, , +17

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer et al. · Nature Chemical Biology · 2015 · 546 citations

, , +8

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

Mark E. Flanagan, Todd A. Blumenkopf, William H. Brissette et al. · Journal of Medicinal Chemistry · 2010 · 335 citations · Full text

, , +17

Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened

Michael J. Munchhof, Qifang Li, Andrei Shavnya et al. · ACS Medicinal Chemistry Letters · 2011 · 160 citations · Full text

, , +16

1–5 of 35